NICE u-turn on treatment for giant cell arteritis
Roche/Chugai’s RoActemra has now won the backing of the National Institute of Health and Care Excellence for the treatment of eligible patients with giant cell arteritis (GCA).
Read More
Tag: IL-6
Janssen’s Plivensia given thumbs down by US advisors
US regulatory advisors are not recommending approval of Johnson & Johnson’s Plivensia for rheumatoid arthritis, having concluded – based on the data available – that the benefits of the drug do not outweigh the potential risks.
Read More
Roche signs deal with Eleven Bio
Roche has bagged access to Eleven Biotherapeutics’ eye disease candidate EBI-031 in a deal worth around $270 million.
Read More
Roche bags Eleven’s experimental eye disease drug
Roche has snapped up rights to an experimental eye disease drug and technology from US biotech Eleven Biotherapeutics in a deal that be worth $270 million.
Read More
